Status:
UNKNOWN
Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Cancer of Stomach
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the efficacy of selective COX-II inhibitor in patients with curative resection performed for locally advanced stomach cancer.
Detailed Description
Cyclo-oxygenase (COX) is a family of enzymes regulating the conversion of arachidonic acid to prostaglandins. COX-II is an inducible enzyme, which may be upregulated when there are stimuli such as inf...
Eligibility Criteria
Inclusion
- Resectable advanced stomach cancer (Tumour stage ≥ T2N1 according to the 5th edition of UICC staging system) without peritoneal or distant metastases.
- Normal renal function
Exclusion
- Solid organ metastases
- Poor performance status
- Already on long-term aspirin or NSAID
- Renal or hepatic dysfunction
- Bleeding disorder
- Hypersensitive to COX-II inhibitors/aspirin/NSAID
- No history of myocardial infarct or stoke
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
214 Patients enrolled
Trial Details
Trial ID
NCT00164892
Start Date
October 1 2004
Last Update
November 17 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Combine Gastro-intestinal Cancer Clinic
Hong Kong, China